Solanezumab

Solanezumab
Monoclonal antibody
TypeWhole antibody
SourceHumanized
TargetBeta amyloid
Clinical data
ATC code
  • none
Legal status
Legal status
  • Investigational
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6396H9922N1712O1996S42
Molar mass144084.24 g·mol−1
 ☒NcheckY (what is this?)  (verify)

Solanezumab (proposed INN, LY2062430[1]) is a monoclonal antibody being investigated by Eli Lilly as a neuroprotector[2] for patients with Alzheimer's disease.[3][4] The drug originally attracted extensive media coverage proclaiming it a breakthrough, but it has failed to show promise in Phase III trials.[5][6]

  1. ^ Farlow M, Arnold SE, van Dyck CH, Aisen PS, Snider BJ, Porsteinsson AP, et al. (July 2012). "Safety and biomarker effects of solanezumab in patients with Alzheimer's disease". Alzheimer's & Dementia. 8 (4): 261–271. doi:10.1016/j.jalz.2011.09.224. PMID 22672770. S2CID 12755108.
  2. ^ International Nonproprietary Names for Pharmaceutical Substances (INN, prepublication copy), World Health Organization.
  3. ^ Clinical trial number NCT00749216 for "Solanezumab Safety Study in Japanese Patients With Alzheimer's Disease" at ClinicalTrials.gov
  4. ^ Clinical trial number NCT00905372 for "Effect of LY2062430 on the Progression of Alzheimer's Disease (EXPEDITION)" at ClinicalTrials.gov
  5. ^ McCartney M (July 2015). "Margaret McCartney: The "breakthrough" drug that's not been shown to help in Alzheimer's disease". BMJ. 351: h4064. doi:10.1136/bmj.h4064. PMID 26208710.
  6. ^ Meglio M (March 10, 2023). "Solanezumab Fails Phase 3 A4 Study of Preclinical Alzheimer Disease". NeurologyLive. Retrieved August 1, 2023.